These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 11904965)

  • 41. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
    Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; Cokgor I; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Regalado LV; Sampson JH; Shafman TD; Wikstrand CJ; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
    J Clin Oncol; 2002 Mar; 20(5):1389-97. PubMed ID: 11870184
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical trials in cellular immunotherapy for brain/CNS tumors.
    Badhiwala J; Decker WK; Berens ME; Bhardwaj RD
    Expert Rev Neurother; 2013 Apr; 13(4):405-24. PubMed ID: 23545055
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunotherapy in human glioblastoma.
    Szabo AT; Carpentier AF
    Rev Neurol (Paris); 2011 Oct; 167(10):668-72. PubMed ID: 21885075
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical effect of human fibroblast interferon (BM532) on malignant brain tumors--with special reference to gliomas].
    Nagai M
    Nihon Gan Chiryo Gakkai Shi; 1989 Mar; 24(3):638-46. PubMed ID: 2671205
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapy for glioma: promises and challenges.
    Han SJ; Zygourakis C; Lim M; Parsa AT
    Neurosurg Clin N Am; 2012 Jul; 23(3):357-70. PubMed ID: 22748649
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advances in gene therapy and immunotherapy for brain tumors.
    Kew Y; Levin VA
    Curr Opin Neurol; 2003 Dec; 16(6):665-70. PubMed ID: 14624074
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning.
    Iizuka A; Komiyama M; Oshita C; Kume A; Ashizawa T; Mitsuya K; Hayashi N; Nakasu Y; Yamaguchi K; Akiyama Y
    Immunol Lett; 2014; 159(1-2):15-22. PubMed ID: 24534640
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cellular immunotherapy for malignant gliomas.
    Lin Y; Okada H
    Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glioma antigen.
    Toda M
    Adv Exp Med Biol; 2012; 746():77-84. PubMed ID: 22639160
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Principles of immunotherapy.
    Liebelt BD; Finocchiaro G; Heimberger AB
    Handb Clin Neurol; 2016; 134():163-81. PubMed ID: 26948354
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy.
    Ogbomo H; Cinatl J; Mody CH; Forsyth PA
    Trends Mol Med; 2011 Aug; 17(8):433-41. PubMed ID: 21507717
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma.
    Fenstermaker RA; Ciesielski MJ
    Expert Rev Vaccines; 2014 Mar; 13(3):377-85. PubMed ID: 24521310
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas.
    Pellegatta S; Cuppini L; Finocchiaro G
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1759-74. PubMed ID: 22050025
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of neuroectodermal antigen by a monoclonal antibody and its application in CSF diagnosis of human glioma.
    Wakabayashi T; Yoshida J; Seo H; Kazo K; Murata Y; Matsui N; Kageyama N
    J Neurosurg; 1988 Mar; 68(3):449-55. PubMed ID: 3343615
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The innate immune response in the central nervous system and its role in glioma immune surveillance.
    Friese MA; Steinle A; Weller M
    Onkologie; 2004 Oct; 27(5):487-91. PubMed ID: 15585981
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dendritic cell therapy with improved outcome in glioma multiforme--a case report.
    Khan JA; Yaqin S
    J Zhejiang Univ Sci B; 2006 Feb; 7(2):114-7. PubMed ID: 16421966
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunobiology of brain tumors.
    Sawamura Y; de Tribolet N
    Adv Tech Stand Neurosurg; 1990; 17():3-64. PubMed ID: 2180410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models.
    Shoji T; Saito R; Chonan M; Shibahara I; Sato A; Kanamori M; Sonoda Y; Kondo T; Ishii N; Tominaga T
    Neuro Oncol; 2016 Aug; 18(8):1120-8. PubMed ID: 26917236
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunobiology and immunotherapeutic targeting of glioma stem cells.
    Madany M; Thomas TM; Edwards L; Yu JS
    Adv Exp Med Biol; 2015; 853():139-66. PubMed ID: 25895711
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intratumorally implanted mesenchymal stromal cells potentiate peripheral immunotherapy against malignant rat gliomas.
    Ströjby S; Eberstål S; Svensson A; Fritzell S; Bexell D; Siesjö P; Darabi A; Bengzon J
    J Neuroimmunol; 2014 Sep; 274(1-2):240-3. PubMed ID: 25086876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.